BRIDGEBIO PHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.09 USD | -3.06% |
|
+3.40% | -25.46% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 4,331 | 8,716 | 2,455 | 1,139 | 7,023 | 5,631 | - | - |
| Enterprise Value (EV) 1 | 3,877 | 8,837 | 3,322 | 2,470 | 8,315 | 6,735 | 7,126 | 7,717 |
| P/E ratio | -14.1 x | -18.7 x | -4.28 x | -2.34 x | -10.2 x | -11.4 x | -10.3 x | -15.9 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 107 x | 1,057 x | 35.2 x | 14.7 x | 755 x | 14.2 x | 22 x | 9.04 x |
| EV / Revenue | 95.6 x | 1,071 x | 47.7 x | 31.8 x | 894 x | 17 x | 27.9 x | 12.4 x |
| EV / EBITDA | -14.6 x | -18.6 x | -5.76 x | -4.89 x | -14 x | -133 x | -15.2 x | -40.4 x |
| EV / FCF | -15.1 x | -21.7 x | -6.5 x | -5.82 x | -15.7 x | -18.4 x | -14.3 x | -19.7 x |
| FCF Yield | -6.61% | -4.61% | -15.4% | -17.2% | -6.36% | -5.44% | -6.99% | -5.08% |
| Price to Book | 9.02 x | 151 x | -2.83 x | -0.91 x | - | -3.62 x | -4.29 x | - |
| Nbr of stocks (in thousands) | 123,575 | 122,568 | 147,192 | 149,483 | 173,967 | 187,129 | - | - |
| Reference price 2 | 35.05 | 71.11 | 16.68 | 7.620 | 40.37 | 30.09 | 30.09 | 30.09 |
| Announcement Date | 3/2/20 | 2/25/21 | 2/24/22 | 2/23/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 40.56 | 8.249 | 69.72 | 77.65 | 9.303 | 396.9 | 255.7 | 623 |
| EBITDA 1 | -266.2 | -474.5 | -576.6 | -505.4 | -593 | -50.58 | -467.9 | -191 |
| EBIT 1 | -266.2 | -474.5 | -576.6 | -512.2 | -607.4 | -380.2 | -566.5 | -393.4 |
| Operating Margin | -656.41% | -5,751.99% | -827.12% | -659.65% | -6,528.75% | -95.8% | -221.57% | -63.15% |
| Earnings before Tax (EBT) 1 | -288.6 | -505.5 | -586.5 | -484.7 | -653.3 | -496.6 | -614.5 | -470.7 |
| Net income 1 | -260.6 | -448.7 | -562.5 | -481.2 | -643.2 | -456.1 | -528.3 | -324.2 |
| Net margin | -642.47% | -5,439.74% | -806.9% | -619.7% | -6,913.92% | -114.93% | -206.64% | -52.05% |
| EPS 2 | -2.480 | -3.800 | -3.900 | -3.260 | -3.950 | -2.633 | -2.908 | -1.889 |
| Free Cash Flow 1 | -256.2 | -407.2 | -511.2 | -424.3 | -529 | -366.2 | -498.4 | -392.1 |
| FCF margin | -631.72% | -4,936.74% | -733.23% | -546.46% | -5,686.62% | -92.28% | -194.95% | -62.95% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/2/20 | 2/25/21 | 2/24/22 | 2/23/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 12.89 | 1.694 | 73.75 | 0.338 | 1.87 | 1.826 | 1.641 | 4.091 | 1.745 | 211.1 | 4.157 | 4.163 | 143.4 | 37.68 | 53.6 |
| EBITDA 1 | -165.6 | -151 | -71.78 | -124.1 | -129.2 | -124.5 | -140.9 | -156.1 | -175.1 | 27.84 | -141.5 | -150 | 258.3 | - | - |
| EBIT 1 | -165.6 | -151 | -80.18 | -124.1 | -129.2 | -126.2 | -146.1 | -157.7 | -177.4 | 0.343 | -187.2 | -186.9 | -56.61 | -156.2 | -146.2 |
| Operating Margin | -1,285.22% | -8,914.76% | -108.72% | -36,715.98% | -6,910.8% | -6,909.26% | -8,903.05% | -3,854.61% | -10,167.11% | 0.16% | -4,503.5% | -4,488.01% | -39.47% | -414.47% | -272.77% |
| Earnings before Tax (EBT) 1 | -152.3 | -201.3 | -2.559 | -140.2 | -140.6 | -142.7 | -160.7 | -179.5 | -170.3 | -36.16 | -214.4 | -208 | -226.5 | -170.5 | -155.6 |
| Net income 1 | -147.2 | -196.4 | -9.856 | -137.3 | -137.6 | -140.2 | -157.9 | -177 | -168.1 | -35.22 | -179.4 | -181.6 | -72.82 | -150 | -135 |
| Net margin | -1,142.15% | -11,593.68% | -13.36% | -40,632.84% | -7,357.81% | -7,675.58% | -9,622.12% | -4,326.55% | -9,635.99% | -16.68% | -4,314.32% | -4,361.41% | -50.78% | -398.06% | -251.88% |
| EPS 2 | -1.010 | -1.350 | -0.0700 | -0.9300 | -0.9200 | -0.9200 | -0.9800 | -1.080 | -0.9600 | -0.2000 | -1.018 | -1.022 | -0.2999 | -0.8300 | -0.7075 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/24/22 | 5/5/22 | 8/4/22 | 11/3/22 | 2/23/23 | 5/4/23 | 8/3/23 | 11/2/23 | 2/22/24 | 5/2/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 121 | 867 | 1,331 | 1,292 | 1,104 | 1,495 | 2,087 |
| Net Cash position 1 | 454 | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | -0.2555 x | -1.504 x | -2.633 x | -2.179 x | -21.83 x | -3.195 x | -10.93 x |
| Free Cash Flow 1 | -256 | -407 | -511 | -424 | -529 | -366 | -498 | -392 |
| ROE (net income / shareholders' equity) | -72.1% | -192% | 138% | - | - | - | - | - |
| ROA (Net income/ Total Assets) | -47.5% | -67.2% | -65.5% | -58.8% | -109% | -82.7% | -82.2% | - |
| Assets 1 | 548.3 | 667.6 | 858.2 | 817.9 | 592 | 551.7 | 643 | - |
| Book Value Per Share 2 | 3.890 | 0.4700 | -5.900 | -8.330 | - | -8.320 | -7.010 | - |
| Cash Flow per Share 2 | - | -3.390 | -3.450 | -2.840 | -3.240 | -2.950 | -1.970 | - |
| Capex 1 | 2.64 | 7.52 | 13.2 | 4.82 | 1.31 | 4.43 | 4.91 | 6.74 |
| Capex / Sales | 6.5% | 91.14% | 19% | 6.21% | 14.04% | 1.12% | 1.92% | 1.08% |
| Announcement Date | 3/2/20 | 2/25/21 | 2/24/22 | 2/23/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
30.09
USD
Average target price
50.54
USD
Spread / Average Target
+67.96%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -25.46% | 5.63B | |
| -2.35% | 90.45B | |
| +3.68% | 41.45B | |
| -10.90% | 33.57B | |
| +58.05% | 25.73B | |
| -19.56% | 14.73B | |
| -9.06% | 12.82B | |
| -11.34% | 11.7B | |
| -43.53% | 11.44B | |
| +3.75% | 8.79B |
- Stock Market
- Equities
- BBIO Stock
- Financials BridgeBio Pharma, Inc.